MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Revenue of MorphoSys AG (MOR)
Revenue in 2023 (TTM): $238.28 M
According to MorphoSys AG's latest financial reports the company's current revenue (TTM) is $238.28 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MorphoSys AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $238.28 M | $179.92 M | $-97,738,116 | $-190,921,521 | $-189,734,199 |
| 2022 | $278.27 M | $229.65 M | $172.8 M | $17.52 M | $-151,057,591 |
| 2021 | $179.6 M | $147.4 M | $-179,200,000 | $-591,100,000 | $-514,500,000 |
| 2020 | $327.7 M | $318.52 M | $127.74 M | $22.49 M | $97.89 M |
| 2019 | $71.76 M | $59.67 M | $-98,874,946 | $-106,520,477 | $-103,014,058 |
| 2018 | $76.44 M | $74.65 M | $-54,937,948 | $-60,476,795 | $-56,172,121 |
| 2017 | $66.79 M | $66.76 M | $-63,024,787 | $-68,790,735 | $-69,826,469 |
| 2016 | $49.74 M | $49.65 M | $-54,979,741 | $-59,863,554 | $-60,382,776 |
| 2015 | $106.22 M | $106.15 M | $22.93 M | $20.63 M | $14.9 M |
| 2014 | $63.98 M | $63.9 M | $-796,236 | $-4,308,715 | $-3,012,629 |
| 2013 | $77.96 M | $77.93 M | $15.52 M | $10.68 M | $13.32 M |
| 2012 | $51.92 M | $51.92 M | $8.9 M | $3.05 M | $1.94 M |
| 2011 | $100.78 M | $93.75 M | $18.09 M | $11.43 M | $8.22 M |
| 2010 | $87.04 M | $79.75 M | $19.33 M | $13.17 M | $9.2 M |
| 2009 | $81.02 M | $74.28 M | $18.39 M | $13.03 M | $8.96 M |
| 2008 | $71.65 M | $64.51 M | $23.23 M | $17.99 M | $13.15 M |
| 2007 | $61.96 M | $69.91 M | $97.34 M | $ | $11.47 M |
| 2006 | $53.03 M | $61.01 M | $87.38 M | $5.29 M | $6.03 M |
| 2005 | $7.98 M | $10.49 M | $38.93 M | $5.11 M | $4.68 M |
| 2004 | $21.98 M | $21.98 M | $3.28 M | $282.11 K | $282.11 K |
| 2003 | $15.31 M | $15.31 M | $-976,450 | $-4,148,011 | $-4,148,032 |
| 2002 | $16.76 M | $16.76 M | $-23,391,477 | $-24,359,210 | $-24,377,294 |